Isadora Ritter Müller, Gabriel Linden, Mariele Feiffer Charão, Marina Venzon Antunes & Rafael Linden • June 12, 2023
Dried blood/plasma spot sampling for therapeutic drug monitoring: challenges and opportunities
A recent publication in Expert Review of Precision Medicine and Drug Development highlights DBS as a reliable and increasingly validated tool for drug monitoring in chronic and complex therapies.
💡 DBS is more than a new sampling method. It transforms how we collect, transport, and analyze pharmacological data — unlocking strategic advantages for:
👩⚕️ Patients:
- Minimally invasive, fingerstick-based collection
- Enables home-based sampling
- Improves comfort and treatment adherence
🩺 Clinicians and care systems:
- Allows more frequent and consistent drug level monitoring
- Supports precise dose adjustments
- Expands monitoring reach to underserved regions
🏭 Pharma industry:
- Accelerates phase 3 and post-market studies with decentralized data
- Lowers logistical costs and infrastructure burden
- Increases diversity in clinical cohorts — essential for variable-response drugs
- Generates real-world data in naturalistic settings
At Health ID, we develop capillary sampling solutions that support TDM with stable, standardized collection and full lab compatibility — helping bridge innovation with real-world application.
The future of TDM is scalable, accessible, and powered by smart sampling.
Share this article: